The clinical importance of hepatitis C genotyping in the United States.
HCV-associated morbidity and mortality
Upon infection, some people note fatigue, loss of appetite, muscle aches, or fever. In most individuals, the immune system is unable to clear the infection and HCV chronic infection progresses over decades, which may lead to liver inflammation and elevated liver enzyme levels. An estimated 20% of individuals infected with HCV will progress to cirrhosis 20 years after infection. (1) Up to 5% of persons with chronic HCV infection per year will progress to advanced cirrhosis and die from HCV-associated liver disease. (1)
HCV infection is the leading indication for liver transplant and accounts for 50% of hepatocellular carcinoma cases. Due to the slow progression of HCV disease, 73.4% of HCV related deaths occur in persons aged 45-64 years, (1) one to four decades after initial infection.
Screening and diagnosis of HCV infection
Traditionally, HCV testing has been recommended for individuals at high risk for HCV transmission. High risk for HCV transmission includes individuals who have participated in injection drug use, undergone chronic hemodialysis, or received blood transfusions or organ transplants before 1992 or clotting factor concentrates manufactured before 1987.3This risk-based testing strategy has had limited success in accurately diagnosing HCV-positive individuals, with 45% of persons with HCV reporting no known exposure risk. (1)
In an effort to diagnose more HCV-positive individuals prior to development of liver disease, the U.S. Centers for Disease Control and Prevention (CDC) recently released new age-based HCV screening guidelines. The CDC study determined that the prevalence of anti-HCV antibodies, which indicate exposure, was highest among persons born during 1945-1965 (at 3.25%), roughly five times higher than adults born in other birth cohorts. Another CDC HCV surveillance study found that persons born between 1945 and 1965 accounted for 58.5% of those who were HCV antibody-positive and 67.2% of those who were HCV RNA-positive. (4) The recent CDC birth cohort screening recommendation states that adults born between 1945 and 1965 should receive one-time testing for HCV, regardless of risk. In an independent review, the U.S. Preventive Services Task Force (USP-STF) also supports the recommendation for birth cohort screening to drive improved health outcomes. The benefits of amended HCV diagnosis guidelines are to identify more infections prior to the onset of liver disease and thus better enable accurate diagnosis of active chronic HCV infection.
Individuals who are screened for or suspected of having acute or chronic HCV should initially be tested for the presence of anti-HCV antibodies. A positive HCV antibody test should be followed with an HCV RNA test to confirm active HCV infection versus prior exposure to HCV. A person with a positive HCV antibody test but who has a negative HCV RNA, should be considered negative for HCV infection. (4)
The recommendation for a diagnostic HCV RNA test is supported by a CDC HCV surveillance study, which found that half of reported HCV infections did not have a positive HCV RNA test. (4) As a result, it was not possible to determine whether the reported HCV infection was an active or previously resolved infection.
The overall goal of the updated CDC recommendation is to improve awareness of HCV infection and drive improved healthcare outcomes. The adoption of birth cohort screening at the same compliance rate as colorectal screening recommendations could identify 400,000 new HCV-infected individuals in the next three years. The use of HCV RNA testing may also improve the accuracy of HCV diagnosis and lead to follow-up medical evaluation.
HCV treatment guidelines
Once diagnosis is confirmed with a nucleic acid HCV RNA test, treatment decisions are based on multiple factors, including the severity of liver disease, the presence of other health issues, patient readiness for treatment, and potential for treatment side effects. The goal of antiviral therapy is to achieve Sustained Virological Response (SVR), defined as undetected HCV virus 24 weeks after completion of therapy. The treatment regimen varies by HCV genotype (Table 1).
HCV Genotype Therapy Duration SVR Rate (5) Genotype 1 Interferon 24-48 weeks 67-75% Ribavirin Protease Inhibitor Genotype 2 Interferon 24 weeks 74% Ribavirin Genotype 3 Interferon 24 weeks 69% Ribavirin Genotype 4 Interferon 48 weeks 60% Ribavirin Genotype 5 No Not applicable N/A guidelines Genotype 6 No Not applicable N/A guidelines Table 1. Current HCV testing guidelines
Duration of treatment for genotype 1 and 4 is based on specific stopping rules related to early virologic response to therapy determined by RNA viral load drop during the first 4 to 24 weeks of therapy. Genotype 1 patients receive triple therapy with pegylated interferon (PEG-IFN), ribavirin (RBV), and one of the FDA-approved protease inhibitors. No formal therapy guidelines exist for genotype 5 and 6 patients, but the typical treatment regimen is PEG-IFN and RBV. Genotype 2 and 3 patients are typically given, and respond well to, PEG-IFN/RBV therapy, with SVR rates of approximately 70%.
The evolution of HCV treatment
HCV therapy in the early 1990s focused on stimulating the patient's innate antiviral immune response with interferon (IFN) therapy. By the 2000s, therapy that included the nonspecific antiviral drug ribavirin in combination with IFN improved SVR rates in genotypes 1-3 two-to threefold. (6)
The first antivirals that specifically targeted HCV, direct acting antivirals (DAAs), were approved in 2011. Two hepatitis C DAAs approved in 2011 prevent viral replication by inhibiting HCV's NS3/NS4 proteases required for hepatitis C virus protein processing. The approval of protease inhibitor DAAs for HCV genotype 1, used together with PEG-IFN and RBV, improved SVR rates from 30% to approximately 60% to 70% SVR.5 Some persons do not reach SVR due to emergence of HCV drug resistance mutations to the protease inhibitors. In particular, HCV genotype 1, subtype A is more prone to developing resistance mutations that can reduce SVR.7 Other potential targets for HCV DAAs include HCV's RNA-dependent RNA polymerase (NS5B) and the viral cofactor protein NS5A, which is required for viral replication.
At present there are more than 25 drug candidates in phase II or phase III clinical trials targeting HCV infection. Three of the leading drug candidates in phase III trials (Sofosbuvir, Faldaprevir, and Simeprevir), used in combination therapy with PEG-IFN plus RBV (P/R), show 80% to 90% SVR rates in individuals with HCV genotypes 1 a/1 b (Table 2). Sofosbuvir is being evaluated on multiple genotypes, which may lead to DAA treatment options for non-genotype 1 individuals. Triple DAA therapy with ABT-450/267/333 plus ritonavir is being evaluated without PEG-IFN to reduce adverse treatment side effects while still delivering~90% SVR. (8)
Drug Class Genotypic Preliminary Activity Data Sotosbuvir NS5B nucleotide Pangenotypic 90% SVR 12 polymerase on genotypes inhibitor 1, 4, 5, and 6 with P/R Faldaprevir NS3A protease Genotype 1 89% SVR12 in inhibitor early virologic response patients with P/R Simoprovir NS3A protease Genotype 1 80% SVR12 inhibitor with P/R ABT-450/RTV NS3/4A protease inhibitor ABT-267 NS5A Genotype 1 88-96% SVR24 non-nucleoside without inhibitor PEG-IFN ABT-333 NS5B non-nucleoside inhibitor Table 2. Investigational phase II/III HCV therapies (3)
Numerous DAA drug candidates are in late-stage trials, and some are currently under priority marketing review, which may lead to FDA approval of these drugs by 2014. Future combination DAA therapy trials are focused on shorter treatment course, activity to all HCV genotypes, and elimination of PEG-IFN and ribavirin from the therapy. Ultimately, if these goals are achieved, the results would be reduced side effects from therapy, reduced drug resistance, and simplified therapy regimens to improve patient compliance through the course of treatment. The rapid advances in DAA development and the large number of clinical trials will likely deliver 8-to-12 week therapy for all genotypes, with SVR rates exceeding 90%, in the coming years.
Importance of accurate HCV genotyping
Hepatitis C virus genotyping is currently used as an aid in determining dose and duration and estimating therapeutic response. Based on the current standard of care, it is critical for patients to receive an accurate genotype, particularly in the case of patients with HCV genotype 1, as they are eligible for combination therapy with FDA-approved protease inhibitors. While the standard of care does not require subtyping of genotype 1, there is significant evidence indicating HCV genotype 1a is more likely to develop drug resistance mutations than genotype 1b. (7) As a result, accurate genotype 1a and 1b subtyping may contribute to clinical decisions, such as beginning therapy immediately or waiting for more effective DAA combination therapy in the near future. It is possible that some of the new DAAs will be approved with genotype-specific indications with variation in dosage or duration for treating specific genotypes.
It is estimated that 3% of the world's population is chronically infected with HCV. (6) In the United States, HCV is an increasing cause of morbidity and mortality and the leading indication for liver transplant. In the last few years the CDC has expanded HCV screening efforts and recommended a new HCV diagnostic algorithm to drive HCV awareness just as new HCV therapies are nearing FDA approval. Expanded screening efforts with early and accurate diagnosis and genotyping are now more important than ever as delivering an effective and accessible cure for HCV becomes a reality.
(1.) CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR. 2012;61(RR-4).
(2.) CDC. Hepatitis C Information for Health Professionals, http://www.cdc.gov/hepatitis/hcv. Accessed September 28, 2013.
(3.) Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
(4.) CDC. Vital signs: evaluating of hepatitis C virus infection testing and reporting-eight U.S. sites, 2005-2011. MMWR. 2013;62(18).
(5.) Feld JJ, Shah H. Hepatology-management of hepatitis C infection, http://www.clinicaloptions.com/inPractice/Hepatology/Hepatology/ch8_Mgmt_of_Hep_Infection/Pages/Page%201.aspx. Accessed September 28, 2013.
(6.) Gaetano JN, Desai AP, Reau N. The era of direct-acting antivirals: The evolving role of interferon and ribavirin for the treatment of chronic hepatitis C. Clin Med Insights: Therapeutics. 2012:(4)39-56.
(7.) Cento V, Mirabelli P, Salpini R, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. http://www.plosone.org/article/info%3Adoi%2F10,1371%2Fjournal.pone.0039652. Accessed September 28, 2013.
(8.) Muir AJ. HCV: Highlights from EASL 2013. http://www.chronicliverdisease.org/disease_focus/ppts/ch/HCV_Highlights_from_EASL_2013Muir.pdf. Accessed September 28, 2013.
Scott O'Brien is a Sr. Product Manager for California-based GenMark Diagnostics.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CE story|
|Publication:||Medical Laboratory Observer|
|Date:||Nov 1, 2013|
|Previous Article:||Viral load monitoring: shifting paradigms in clinical practice.|
|Next Article:||Challenges for accurate HIV diagnosis: viral genetic diversity and acute infection.|